Slow Capital Inc. Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Slow Capital Inc. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 7,909 shares of the medical research company’s stock after selling 121 shares during the quarter. Slow Capital Inc.’s holdings in Thermo Fisher Scientific were worth $2,323,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Truvestments Capital LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $29,000. Capital Advisors Ltd. LLC grew its position in Thermo Fisher Scientific by 250.0% during the second quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock worth $41,000 after buying an additional 100 shares in the last quarter. Focused Wealth Management Inc purchased a new position in Thermo Fisher Scientific during the second quarter worth about $44,000. Farmers & Merchants Trust Co of Chambersburg PA grew its position in Thermo Fisher Scientific by 168.0% during the first quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock worth $55,000 after buying an additional 126 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new position in Thermo Fisher Scientific during the first quarter worth about $64,000. Institutional investors own 88.21% of the company’s stock.

In related news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $268.29, for a total transaction of $670,725.00. Following the transaction, the chief financial officer now owns 40,029 shares in the company, valued at approximately $10,739,380.41. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the transaction, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The disclosure for this sale can be found here. In the last three months, insiders sold 52,775 shares of company stock valued at $14,986,676. 0.45% of the stock is currently owned by corporate insiders.

Several equities analysts recently commented on TMO shares. Needham & Company LLC boosted their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Bank of America reaffirmed a “buy” rating and set a $300.00 price target (up previously from $285.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, April 16th. UBS Group lifted their price target on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Finally, Wolfe Research assumed coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $303.17.

Shares of NYSE TMO traded up $3.41 during midday trading on Tuesday, reaching $275.41. The company had a trading volume of 83,970 shares, compared to its average volume of 1,615,221. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49. The company’s fifty day simple moving average is $288.55. The company has a market cap of $110.68 billion, a PE ratio of 24.77, a PEG ratio of 1.81 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, beating analysts’ consensus estimates of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. During the same quarter in the previous year, the company posted $2.75 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 3.9% on a year-over-year basis. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.23 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.28%. The ex-dividend date is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.